Ingredient comparison Nº 43 / Head-to-head
Tranexamic Acid vs Vitamin C
Tranexamic acid is the more targeted pigment fighter for melasma; vitamin C is the broader antioxidant with collagen and photoprotection benefits.
Tranexamic acid (TXA, 2–5% topical) and L-ascorbic acid (vitamin C, 10–20%) both address hyperpigmentation but through fundamentally different mechanisms and with different evidence profiles. Tranexamic acid acts upstream on keratinocyte signaling — inhibiting the plasminogen-to-plasmin pathway that stimulates melanocytes to produce more melanin after UV or inflammation — and additionally suppresses angiogenesis (the vascular/redness component of melasma). A 2017 meta-analysis of 11 studies (667 participants) confirms TXA reduces MASI by 1.60 points; a split-face RCT found 3% TXA equivalent to 4% hydroquinone at 8 weeks. Vitamin C (L-ascorbic acid) inhibits tyrosinase enzymatically at the copper active site, provides direct antioxidant/photoprotective activity against UV-induced reactive oxygen species, and is a required cofactor for collagen hydroxylase enzymes. Its main challenge is formulation stability — it oxidises rapidly in aqueous solution. For melasma specifically, TXA has the stronger targeted evidence; for broad photoprotection, antioxidant defense, and collagen support, vitamin C is the more multifunctional ingredient.
02 / Head-to-head
Compared dimension by dimension
Each row shows what the evidence actually says for both ingredients on that dimension. Edge = which ingredient has the stronger case, or "no clear edge" when evidence is comparable or insufficient for a call.
| Dimension | Tranexamic Acid | L-Ascorbic Acid (Vitamin C) | Edge |
|---|---|---|---|
| Pigmentation mechanism | Upstream keratinocyte signal inhibitor: blocks plasminogen-to-plasmin conversion, reducing UV/inflammation-triggered arachidonic acid release and prostaglandin signaling that stimulates melanocytes. Additionally inhibits VEGF receptor signaling, targeting the vascular/angiogenesis component of melasma — a mechanism distinct from any tyrosinase inhibitor. 15 | Tyrosinase inhibition at the copper active site via reduction of the catalytic copper ion.Reduces melanin production enzymatically. In vitro tyrosinase inhibition is well-established; dedicated large-scale clinical RCT evidence for L-ascorbic acid monotherapy on pigmentation is more limited than its mechanistic evidence. 12 | Advantage: Tranexamic Acid |
| Melasma clinical evidence | Strongest evidence base of any non-hydroquinone topical agent for melasma.Meta-analysis of 11 studies (667 participants): TXA monotherapy reduced MASI by 1.60 points (p<0.001). Split-face RCT (n=20): 3% TXA equivalent to 4% hydroquinone in mMASI reduction at 4 and 8 weeks. 2025 RCT (n=99): TXA 5% + niacinamide 4% equivalent to 4% hydroquinone with fewer adverse effects. 234 | L-ascorbic acid lacks dedicated large-scale melasma RCTs equivalent to TXA's evidence base.Mechanistic evidence for tyrosinase inhibition is robust in vitro. Vitamin C is included in many multi-ingredient brightening regimens but its isolated contribution to melasma MASI score reduction has not been established in powered standalone trials. 12 | Advantage: Tranexamic Acid |
| Antioxidant & UV photoprotection | Tranexamic acid is not a primary antioxidant in the free-radical scavenging sense.Its anti-melanogenic activity is mediated through the plasminogen/prostaglandin and VEGFR pathways, not direct ROS neutralisation. It does not provide significant direct UV photoprotective activity. | L-ascorbic acid is the benchmark topical antioxidant.At 15%, it directly scavenges reactive oxygen species generated by UV exposure. Combined with 1% alpha-tocopherol (vitamin E), antioxidant protection factor reaches approximately 4-fold after 4 daily applications. Tissue levels persist ~4 days after discontinuation. 1110 | Advantage: L-Ascorbic Acid (Vitamin C) |
| Collagen synthesis support | No documented collagen synthesis mechanism.Tranexamic acid's mechanisms are pigment- and vascular-focused. No published data on TXA's effect on collagen or dermal remodeling. | Required cofactor for prolyl hydroxylase and lysyl hydroxylase — the enzymes that stabilize the triple-helix collagen structure. Without adequate vitamin C, newly synthesized collagen cannot be properly hydroxylated. This is a well-established biochemical mechanism, supported by the historic evidence on scurvy and wound healing. 10 | Advantage: L-Ascorbic Acid (Vitamin C) |
| Formulation stability | Highly stable.Aqueous solutions retained above 97% active ingredient after 31 days at room temperature. No oxidative degradation, no light sensitivity, no discolouration. Does not require low-pH, opaque, or airless packaging. Broad formulation pH tolerance (approximately 4–7). 6 | Notoriously unstable in aqueous formulations.Oxidises on contact with air, light, and trace metal ions; turns yellow then brown. Requires opaque, airless packaging. Ferulic acid co-stabilises it and doubles photoprotection. Shelf-life post-opening highly variable — a visually browned product has meaningfully degraded. 1413 | Advantage: Tranexamic Acid |
| Tolerability & pH requirements | Excellent tolerability.Multiple clinical trials at 2–5% report no significant adverse events. Can be formulated at physiological pH 4–7 without requiring the aggressive low-pH environment needed by L-ascorbic acid. Suitable for sensitive skin and post-procedure use. 3 | Requires pH below 3.5 for meaningful skin penetration — inherently irritating to many skin types. Transient stinging on application is common. Not suitable for reactive or sensitive skin at full therapeutic concentrations. The low-pH requirement is a fundamental formulation constraint that cannot be bypassed without compromising delivery. 1014 | Advantage: Tranexamic Acid |
03 / The decision
Which one is right for you?
Choose Tranexamic Acid if…
- Your primary concern is melasma or UV-triggered stubborn pigmentation — tranexamic acid has the strongest clinical trial evidence of any non-hydroquinone topical for MASI reduction
- You have sensitive skin that cannot tolerate L-ascorbic acid's low-pH requirement, but still want an evidence-backed brightening active
- You want a stable brightening active that does not oxidise, discolour, or require special packaging
- You want to target the vascular/redness component of melasma alongside the pigmentation component — only TXA addresses both through VEGFR inhibition
- You are building a multi-brightener stack and want to address the upstream signaling step (keratinocyte-to-melanocyte communication) as a complement to a tyrosinase inhibitor
Choose L-Ascorbic Acid (Vitamin C) if…
- Antioxidant photoprotection is a primary goal — L-ascorbic acid is the best-evidence topical antioxidant for UV defense and is used as a morning antioxidant layer under SPF
- You want to support collagen synthesis through the established hydroxylase cofactor mechanism, which tranexamic acid lacks entirely
- Your primary concern is broad photoaging — fine lines, dullness, overall skin quality — rather than targeted melasma treatment specifically
- You already use a dedicated SPF and want to stack antioxidant protection: vitamin C + vitamin E + ferulic acid provides approximately 4-fold antioxidant protection factor against UV-induced oxidative damage
- You want the broadest multi-mechanism active (antioxidant + tyrosinase inhibitor + collagen cofactor) rather than the most targeted melasma agent
Shop these actives
Buy The INKEY List on Amazon $18.00 Tranexamic Acid · affiliate link
Buy Geek & Gorgeous on Amazon $14.90 L-Ascorbic Acid (Vitamin C) · affiliate link
04 / Stacking
Can you use both?
Can you combine Tranexamic Acid and L-Ascorbic Acid (Vitamin C)?
Tranexamic acid and L-ascorbic acid are compatible and frequently combined in brightening routines. Their mechanisms are entirely complementary: TXA acts on the upstream keratinocyte signaling that drives melanin production; vitamin C inhibits tyrosinase and provides antioxidant defense. Layering is straightforward: apply vitamin C (which requires low pH, so apply first on clean skin) and allow it to absorb, then apply tranexamic acid (which is pH-tolerant and stable at a wider range). No chemical incompatibility between the two has been documented. Expert consensus on topical melasma management includes TXA as compatible with ascorbic acid as complementary agents addressing different pathway steps.
05 / Questions
Frequently asked
- Which is better for dark spots — tranexamic acid or vitamin C?
- For melasma specifically, tranexamic acid has the stronger targeted evidence: a 2017 meta-analysis (11 studies, 667 participants) confirmed TXA significantly reduces MASI scores, and a split-face RCT found 3% TXA equivalent to 4% hydroquinone. For general dark spots and photoaging, vitamin C's tyrosinase inhibition plus antioxidant protection provides broader coverage. The choice depends on the type of pigmentation: TXA is the more targeted choice for inflammatory or UV-triggered melasma; vitamin C is the more multifunctional choice for overall skin tone, antioxidant defense, and collagen support. 2312
- Can I use vitamin C and tranexamic acid together?
- Yes, and the combination is well-supported by their complementary mechanisms. Vitamin C acts at tyrosinase (blocking melanin production enzymatically) and provides antioxidant photoprotection. Tranexamic acid acts upstream, interrupting the keratinocyte signals that stimulate melanocytes after UV or inflammation. A review of topical melasma treatments identifies TXA as compatible with ascorbic acid as complementary agents addressing different steps in the melanogenesis cascade. For layering: apply vitamin C first (it requires pH below 3.5 for skin penetration, so it should go on first before other products raise the surface pH); let it absorb; then apply TXA which is pH-tolerant. 710
- Does tranexamic acid cause blood clots when used on skin?
- No. The blood clot concern originates from oral tranexamic acid used at 3–6 g/day for surgical hemostasis — doses orders of magnitude higher than any cosmetic topical use. Even at the low dermatological oral dose (250–500 mg/day for melasma), a 2025 multicenter propensity-matched cohort study found no association with thromboembolic events. For topical cosmetic application at 2–5%, systemic absorption is minimal. Multiple clinical trials of topical TXA report no systemic adverse events. The antifibrinolytic risk is dose- and route-dependent and is not transferable from surgical oral dosing to topical cosmetic use. 983
06 / References
Sources
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14